acute ischemic stroke
Conditions
Interventions
High-dose experimental group:Ginkgo diterpene lactone meglumine injection 3 doses +aspirin
Medium-dose experimental group:Ginkgo diterpene lactone meglumine injection 2 doses + ginkgo diterpene lactone meglumine injection simulator 1 dose + aspirin
Low-dose experimental group:Ginkgo diterpene lactone meglumine injection 1 dose + Ginkgo diterpene lactone meglumine injection simulator 2 doses + aspirin
Control placebo group:Ginkgo diterpene lactone meglumine injection simulator 3 doses + aspirin
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) 40 = age = 80 years old, male or female; (2) Acute ischemic stroke within 4.5-48 hours after the onset of the disease was diagnosed by clear evidence; (3) The first onset, or the previous onset without relevant serious sequelae (mRS = 2 before this onset); (4) NIHSS score = 5 and = 24; (5) Understand and voluntarily sign the informed consent form for research.
Exclusion criteria
Exclusion criteria: (1) Non-vascular intracranial diseases (such as intracranial tumors, multiple sclerosis, etc.); (2) Imaging examination showed that the area of cerebral infarction was greater than 1/2 of the single lobe area; (3) The imaging examination showed that this cerebral infarction had post-infarction hemorrhage transformation; (4) Patients with contraindications to the use of ginkgo preparations or aspirin; (5) MRS was greater than 2 points before onset; (6) There was severe hepatic insufficiency or renal insufficiency before randomization; (7) Previous history of intracranial hemorrhage (such as ICH, SAH); (8) There is a history of gastrointestinal bleeding or major surgery in the past 90 days; (9) Suffer from serious organic disease, and the expected survival time is less than 90 days; (10) Pregnant women or women of childbearing age who have not taken effective contraceptive measures and have no pregnancy test records; (11) Other experimental drugs or instruments are being tested; (12) Unable to cooperate to complete 90-day event follow-up due to geographical or other reasons (such as alcoholism, drug abuse or dementia, serious mental illness, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| national Institute of Health stroke scale (NIHSS);CT perfusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| modified Rankin Scale (mRS); | — |
Countries
China
Contacts
Public ContactHan Yan
Shanghai University of Traditional Chinese Medicine Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine
Outcome results
None listed